Study S000949

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06222437
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: WITHDRAWN
Enrollment: 0
Start: 2026-02
Primary completion: 2026-02
Lead sponsor: Methodist Health System
Conditions: Polycystic Ovary Syndrome
Interventions: DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number of appropriate weekly dose [4 weeks]
Number of days on therapy [4 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.